Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scholar Rock Holding Corporation (SRRK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Scholar Rock files reports and current updates with the U.S. Securities and Exchange Commission (SEC) that describe its financial condition, clinical and regulatory milestones, capital markets activity, and material corporate events.
For SRRK, Form 8-K current reports are particularly important. Recent 8-K filings have covered quarterly financial and operating results, conference call presentations, and key regulatory developments such as the U.S. Food and Drug Administration’s Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) in spinal muscular atrophy (SMA). Other 8-Ks describe the inspection status of a third-party fill-finish facility, the use of an at-the-market equity offering program with Jefferies LLC, and the filing of a prospectus supplement for additional common stock issuance.
Scholar Rock’s filings also document its status as a registrant on The Nasdaq Global Select Market under the ticker SRRK, the terms of its common stock, and its use of a shelf registration statement on Form S-3ASR. Inducement equity awards granted under the company’s 2022 Inducement Equity Plan are reflected in press releases that may be furnished as exhibits to 8-Ks, providing detail on stock options and restricted stock units granted to new employees.
On Stock Titan, users can review these SEC documents alongside AI-powered summaries that explain the main points of each filing in accessible language. Real-time updates from EDGAR help surface new 8-Ks, 10-Q quarterly reports, 10-K annual reports, and any future registration statements or prospectus supplements related to Scholar Rock’s capital-raising activities. For investors analyzing SRRK’s SMA and broader neuromuscular disease programs, these filings offer primary-source insight into clinical progress, regulatory interactions, financing plans, and overall corporate strategy.
Jeffrey S. Flier, Director of Scholar Rock Holding Corp (SRRK), executed several transactions on June 23, 2025, as part of a pre-planned Rule 10b5-1 trading plan established on February 27, 2025:
- Exercised 20,316 stock options at $21.62 per share
- Sold 17,550 shares at weighted average price of $32.16
- Sold 2,766 shares at weighted average price of $32.74
- Sold 11,136 shares at weighted average price of $33.21 (held in family trust)
Following these transactions, Flier directly owns 24,070 shares (including 16,438 common shares and 7,632 RSUs) and indirectly owns 11,136 shares through The Jeffrey S. Flier Family Trust - 2014. The exercised stock option has no remaining unvested shares. These transactions represent a significant reduction in Flier's direct holdings, suggesting potential portfolio rebalancing or profit-taking with the stock trading above $32.